In addition to EGFR and ALK, a spectrum of less common oncogenic drivers—including ROS1, BRAF, MET, RET, NTRK, and others—has been identified, with targeted therapies either available or under active investigation, highlighting the growing complexity and precision of NSCLC management [5,6]. This evidence concerns the gene ALK and non-small cell lung carcinoma.